Measuring effects on intima media thickness: An evaluation of rosuvastatin in subclinical atherosclerosis - The rationale and methodology of the METEOR study

Cardiovascular Drugs and Therapy

Volumn 18, Issue 3, 2004, Pages 231-238

  Crouse III, John Robert ^a   Grobbee, Diederick E ^b   O'Leary, Daniel H ^c   Bots, Michiel L ^b   Evans, Gregory W ^a   Palmer, Mike K ^d   Riley, Ward A ^a   Raichlen, Joel S ^d  

^a WAKE FOREST UNIVERSITY   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c TUFTS MEDICAL CENTER   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

asymptomatic atherosclerosis; B mode ultrasound; carotid; intima media thickness; statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN;

ADULT; AGED; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAROTID ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EUROPE; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; UNITED STATES;

ARTERIOSCLEROSIS; C-REACTIVE PROTEIN; CAROTID STENOSIS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FLUOROBENZENES; HUMANS; LIPID METABOLISM; LIPIDS; MULTICENTER STUDIES; PATIENT SELECTION; PROSPECTIVE STUDIES; PYRIMIDINES; SULFONAMIDES; TIME FACTORS; TUNICA INTIMA; TUNICA MEDIA; ULTRASONOGRAPHY;

EID: 2542592150     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:CARD.0000033645.55138.3d     Document Type: Article

References (47)

1. Thaulow E, Erikssen J, Sandvik L, Erikssen G, Jorgensen L, Cohn PF. Initial clinical presentation of cardiac disease in asymptomatic men with silent myocardial ischemia and angiographically documented coronary artery disease (the Oslo Ischemia Study). Am J Cardiol 1993;72:629-633.
2. Raggi P. The use of electron-beam computed tomography as a tool for primary prevention. Am J Cardiol 2001;88(Suppl J):28J-32J.
3. Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 1992;2:23-28.
4. Law MR, WaLd NJ, Wu T, Hackshaw A, Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: Data from the BUPA study. BMJ 1994;308:363-366.
5. Knopp RH. Drug treatment of lipid disorders. New Engl J Med 1999;341:498-511.
6. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
7. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307.
8. Sacks FM, Pfeffer MA, Moye LA, et al. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
9. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AF-CAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-1622.
10. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.
11. Gotto AM Jr, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000;101:477-484.
12. Heart Protection Study collaborative group. The MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial. Lancet 2002;56:53-56.
13. Sever PS, Dahlof B, Poulter NR, et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering-Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003;361:1149-1158.
14. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998;19:1434-1503.
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
16. Grouse JR 3rd, Byington EP, Bond MG, et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 1995;75:455-459.
17. Hodis HN, Mack WJ, LaBree L, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy. Ann Intern Med 1996;124:548-556.
18. MacMahon S, Sharpe N, Gamble G, et al. Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis: Results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation 1998;97:1784-1790.
19. Furberg CD, Adams HPJr, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994;90:1679-1687.
20. Salonen R, Nyyssonen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995;92:1758-1764.
21. Mercuri M, Bond MG, Sirtori CR, et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: The Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 1996;101:627-634.
22. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial. Lancet 2001;357:577-581.
23. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002;106:2055-2060.
24. Olsson AG, McTaggart F, Raza A. Rosuvastatin: A Highly Effective New HMG-CoA Reductase Inhibitor. Cardiovasc Drug Rev 2002;20:303-328.
25. Ubels FL, Terpstra WF, Smit AJ. Carotid intima media thickness: Influence of drug treatment and clinical implications. Neth J Med 1999;55:188-195.
26. Espeland MA, Craven TE, Riley WA, Corson J, Romont A, Furberg CD. Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke 1996;27:480-485.
27. SAS Institute Inc. SAS/STAT User's Guide, Version 8, Cary, NC, 1999.
28. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000;102:1503-1510.
29. Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: The study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001;103:919-925.
30. de Groot E, Jukema JW, van Swijndregt ADM, et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: A report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol 1998;31:1561-1567.
31. Byington RP, Furberg CD, Grouse JR, Espeland MA, Bond MG. Pravastatin, Lipids and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 1995;76:54C-59C.
32. Gotto AM Jr, Farmer JA. Pleiotropic effects of statins: Do they matter? Curr Opin Lipidol 2001;12:391-394.
33. Liao JK. Beyond lipid lowering: The role of statins in vascular protection. Int J Cardiol 2002;86:5-18.
34. Jones PH, Davidson MH, Stein EA, et al. for the STELLAR Study Group. Comparison of efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003;92:152-160.
35. Grouse JR 3rd, Craven TE, Hagaman AP, Bond MG. Association of coronary disease with segment-specific intimal-medial thickening of the extracranial carotid artery. Circulation 1995;92:1141-1147.
36. Bots ML, Witteman JC, Grobbee DE. Carotid intima-media wall thickness in elderly women with and without atherosclerosis of the abdominal aorta. Atherosclerosis 1993;102:99-105.
37. Mattace Raso F, Rosato M, Talerico A, Cotronei P, Mattace R. Intimal-medial thickness of the common carotid arteries and lower limbs atherosclerosis in the elderly. Minerva Cardioangiol 1999;47:321-327.
38. Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 1993;87(Suppl II):II56-II65.
39. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam Study. Circulation 1997;96:1432-1437.
40. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: The Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 1997;146:483-494.
41. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999;340:14-22.
42. Iglesias del Sol A, Bots ML, Grobbee DE, Hofman A, Witteman JC. Carotid intima-media thickness at different sites: Relation to incident myocardial infarction. The Rotterdam Study. Eur Heart J 2002;23:934-940.
43. Belcaro G, Nicolaides AN, Laurora G, et al. Ultrasound morphology classification of the arterial wall and cardiovascular events in a 6-year follow-up study. Arterioscler Thromb Vasc Biol 1996;16:851-856.
44. Bots ML, Grobbee DE. Intima media thickness as a surrogate marker for generalised atherosclerosis. Cardiovasc Drugs Ther 2002;16:341-351.
45. Greenland P, Abrams J, Aurigemma GP, et al. Prevention Conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention: Noninvasive tests of atherosclerotic burden: Writing Group III. Circulation 2000;101:E16-E22.
46. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: A direct measurement with ultrasound imaging. Circulation 1986;74:1399-1406.
47. Grobbee DE, Bots ML. Statin treatment and progression of atherosclerotic plaque burden. Drugs 2003;63:893-911.